Kuros Biosciences Ltd.

Share Issue/Capital Change • May 10, 2012

News Details

Ad-hoc | 10 May 2012 20:30

Cytos Biotechnology Ltd. raises an additional CHF 3.2 million via Rights Offering

Cytos Biotechnology AG / Key word(s): Capital Increase

10.05.2012 20:30

Release of an ad hoc announcement pursuant to Art. 53 KR

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO
OR FROM THE UNITED STATES OF AMERICA (THE 'UNITED STATES' OR 'U.S.'),
CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

MEDIA RELEASE - COMMUNIQUE AUX MEDIAS - MEDIENMITTEILUNG

Cytos Biotechnology Ltd. raises an additional CHF 3.2 million via Rights
Offering

Schlieren (Zurich), Switzerland, May 10, 2012 - Cytos Biotechnology Ltd.
('Cytos') announced today the results of the rights offering launched in
April 2012. The shareholders were offered the opportunity to subscribe for
7 new registered shares at a subscription price of CHF 1.87 each for 15
existing registered shares. 63.9% of the subscriptions rights were
exercised and, accordingly, 1'709'700 new registered shares will be issued
to the shareholders.

The completion of the rights offering with the issuance of the shares
subscribed by the existing shareholders is subject to the completion of the
investor capital increase as approved by the shareholders of Cytos on April
20, 2012. Cytos expects that the share capital increase in the total
nominal amount of CHF 1'665'137.50 corresponding to 16'651'375 new
registered shares, will be registered in the commercial register on
May 14, 2012 and that trading in these new registered shares on the SIX
Swiss Exchange will commence on May 15, 2012.

The total gross proceeds resulting from the shareholder tranche and the
investor capital increase (not including the funds to be provided by the
investors by way of convertible loan notes) are expected to be CHF
26'947'133.84.

For a detailed description of the capital increase as well as the
recapitalisation of Cytos please refer to the offering and listing
prospectus and the supplement, which can be obtained free of charge from
Neue Helvetische Bank AG (phone: +41 44 204 56 19, email:
prospectus@nhbag.ch) or Cytos Biotechnology AG (phone: +41 44 733 47 47,
email: info@cytos.com).

For further information please contact:

Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel.: +41 44 733 46 46
e-Mail: harry.welten@cytos.com
Website: www.cytos.com

About Cytos Biotechnology Ltd
Cytos Biotechnology Ltd is a Swiss public biotechnology company that
specializes in the development and commercialization of a new class of
biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM) are
intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce the desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Cytos' Immunodrug(TM) candidates are being developed both
in-house and together with Novartis, Pfizer and Pfizer Animal Health.
Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology
(ETH) in Zurich, the Company is located in Schlieren (Zurich). Cytos
Biotechnology Ltd is listed according to the Main Standard of the SIX Swiss
Exchange Ltd under the symbol CYTN.

This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The Company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments.

THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR THE SOLICITATION OF AN
OFFER TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES TO ANY PERSON IN
AUSTRALIA, CANADA, JAPAN, OR THE UNITED STATES OR IN ANY OTHER
JURISDICTION, NOR DOES IT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF
ARTICLE 652A OR 1156 OF THE SWISS CODE OF OBLIGATIONS OR A LISTING
PROSPECTUS PURSUANT TO THE LISTING RULES OF THE SIX SWISS EXCHANGE LTD. ANY
DECISION TO PURCHASE ANY SECURITIES REFERRED TO HEREIN SHOULD BE SOLELY
BASED ON THE RELEVANT PROSPECTUS. IN ADDITION, THE OFFER AND SALE OF THE
SECURITIES REFERRED TO HEREIN HAS NOT BEEN AND WILL NOT BE REGISTERED UNDER
THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE 'SECURITIES ACT') OR UNDER
THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. THE
SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN
THE UNITED STATES ABSENT REGISTRATION UNDER THE SECURITIES ACT OR AN
APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. SUBJECT TO CERTAIN
EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN
AUSTRALIA, CANADA OR JAPAN OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY
NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THERE WILL BE
NO PUBLIC OFFER OF THE SECURITIES IN THE UNITED STATES.

IN THE UNITED KINGDOM, THIS PRESS RELEASE IS DIRECTED ONLY AT (I) PERSONS
WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING
WITHIN ARTICLE 19(1) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000
(FINANCIAL PROMOTION) ORDER 2005 (THE 'ORDER'), AND (II) HIGH NET WORTH
ENTITIES FALLING WITHIN ARTICLE 49(2) OF THE ORDER, AND (III) PERSONS TO
WHOM IT WOULD OTHERWISE BE LAWFUL TO DISTRIBUTE IT.

IN ADDITION, IF AND TO THE EXTENT THAT THIS PRESS RELEASE IS COMMUNICATED
IN, OR THE OFFER OF SECURITIES TO WHICH IT RELATES IS MADE IN, ANY EEA
MEMBER STATE THAT HAS IMPLEMENTED DIRECTIVE 2003/71/EC (TOGETHER WITH ANY
APPLICABLE IMPLEMENTING MEASURES IN ANY MEMBER STATE, THE 'PROSPECTUS
DIRECTIVE'), THIS PRESS RELEASE AND THE OFFERING OF ANY SECURITIES
DESCRIBED HEREIN ARE ONLY ADDRESSED TO AND DIRECTED AT PERSONS IN THAT
MEMBER STATE WHO ARE QUALIFIED INVESTORS WITHIN THE MEANING OF THE
PROSPECTUS DIRECTIVE (OR WHO ARE OTHER PERSONS TO WHOM THE OFFER MAY
LAWFULLY BE ADDRESSED) AND MUST NOT BE ACTED ON OR RELIED ON BY OTHER
PERSONS IN THAT MEMBER STATE.

10.05.2012 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital
market and press releases.
The EquityStory Group distributes authentic and real-time financial news
for over 1'300 listed companies.
The Swiss news archive can be found at www.equitystory.ch/news

---

Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open
Market in Frankfurt; SIX

End of Announcement EquityStory News-Service

---